The Journal of Experimental Medicine · 2002 · 130 citations · 35 references
Life SciencesImmunologyOncologyCancer ImmunologyCellular ImmunologyTumor ImmunologyAntigen PresentationAntigen RecognitionAntitumor T Cell ResponsesT Cell ActivationT Cell Responses To TumorsTumor AntigensAntigen Presenting CellsCd4 T Cell ActivationEpitope SelectionImmunodominant AntigensProfessional Antigen-presenting CellsT Cell Epitope RecognitionT-cell Responses To Tumor AntigensTumor Antigen Recognition
Long-lasting tumor immunity requires functional mobilization of CD8+ and CD4+ T lymphocytes. CD4+ T cell activation is enhanced by presentation of shed tumor antigens by professional antigen-presenting cells (APCs), coupled with display of similar antigenic epitopes by major histocompatibility complex class II on malignant cells. APCs readily processed and presented several self-antigens, yet T cell responses to these proteins were absent or reduced in the context of class II+ melanomas. T cell recognition of select exogenous and endogenous epitopes was dependent on tumor cell expression of gamma-interferon-inducible lysosomal thiol reductase (GILT). The absence of GILT in melanomas altered antigen processing and the hierarchy of immunodominant epitope presentation. Mass spectral analysis also revealed GILT's ability to reduce cysteinylated epitopes. Such disparities in the profile of antigenic epitopes displayed by tumors and bystander APCs may contribute to tumor cell survival in the face of immunological defenses.
35
Balasubramanian Arunachalam, Uyen Phan, Hans J. Geuze et al. · Proceedings of the National Academy of Sciences · 2000 · 427 citations
Markus Maeurer, Susanne M. Gollin, D Martin et al. · Journal of Clinical Investigation · 1996 · 286 citations · Full text
Life Sciences, Immunology, Oncology +17